201 results
Page 3 of 11
6-K
EX-99.1
5w4ugmt
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
wwz8u4 4sk522fijp9
30 May 23
Current report (foreign)
6:11am
6-K
x2yiomx ik67e0z
17 May 23
Current report (foreign)
6:02am
6-K
mjdskigbkhrxnan6h6
11 May 23
Current report (foreign)
6:10am
6-K
8sfdnq
11 May 23
Current report (foreign)
6:07am
6-K
pyubb7l7bisy oh
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
4hg5tz e0474slhydt9
21 Dec 22
Current report (foreign)
6:01am
6-K
s6csxg qu3y78r
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
bcvh0tx4mkw
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
3j5em 77qu
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
9gg x62l3zvkdiwl5qdk
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
nw8d8bi4j 9n
30 Nov 22
Current report (foreign)
6:28am
6-K
mxt44mi0
4 Nov 22
Current report (foreign)
6:01am
6-K
25e01o
27 Oct 22
Current report (foreign)
6:01am
6-K
20z52
14 Oct 22
Current report (foreign)
7:36am
6-K
8djtckwztw77i59 rbi
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
9w88n 5j0fxs7lrp
23 Aug 22
Current report (foreign)
6:13am
6-K
lef8koxhgnhwl8qobv
4 Aug 22
Current report (foreign)
6:07am
6-K
dwxuroa3 eg
28 Jul 22
Current report (foreign)
6:09am
6-K
vy3kh
11 Jul 22
Current report (foreign)
6:05am